User menu

Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy.

Bibliographic reference Hantson, Philippe ; Luyasu, S ; Haufroid, Vincent ; Lambert, Michel. Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy.. In: Pharmacotherapy, Vol. 20, no. 9, p. 1141-3 (2000)
Permanent URL http://hdl.handle.net/2078.1/8639
  1. Hantson PH, Pharmacotherapy, 16, 869 (1996)
  2. Rees P.H., Kager P.A., Keating M.I., Hockmeyer W.T., RENAL CLEARANCE OF PENTAVALENT ANTIMONY (SODIUM STIBOGLUCONATE), 10.1016/s0140-6736(80)90120-8
  3. Gebel T., Claussen K., Dunkelberg H., Human biomonitoring of antimony, 10.1007/s004200050273
  4. Berman J. D., Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years, 10.1093/clind/24.4.684
  5. Veiga J.P.R., Wolff E.R., Sampaio R.N., Marsden P.D., RENAL TUBULAR DYSFUNCTION IN PATIENTS WITH MUCOCUTANEOUS LEISHMANIASIS TREATED WITH PENTAVALENT ANTIMONIALS, 10.1016/s0140-6736(83)90595-0
  6. Chulay J.D., Fleckenstein L., Smith D.H., Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate, 10.1016/0035-9203(88)90267-2
  7. Sampaio RN, Rev Soc Bras Med Trop, 30, 457 (1997)
  8. Buffet P, Nephrol Dial Transplant, 10, 1477 (1995)